Hsi-Hsun Lin, MD PhD

Kaohsiung Veterans General Hospital, Taiwan

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-792) Evaluation of the efficacy and safety of a short-course, daily, 4-month regimen including isoniazid, pyrazinamide, rifapentine and moxifloxacin (2HZPM/2HPM) for the treatment of drug-susceptible pulmonary tuberculosis in Taiwan (ESCAPE-TB): A multicenter study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-1367) Changing Epidemiology of Carbapenemase-producing Carbapenem-resistant Enterobacterales (CRE) in Taiwan
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT

• (P-1368) High prevalence of class 1 integrons in carbapenem resistant Enterobacterales in Taiwan.
  Friday, October 18, 2024

  12:15 PM – 1:30 PM US PT